Exclusively sold by Medtronic (NYSE: MDT), the device’s implant, delivery and blood flow reversal system picked up a premarket approval, while its umbrella-like filter designed to stop clots and other particles from reaching the brain obtained an additional 510(k) clearance.
Contego’s three-in-one approach combines a nitinol stent, balloon and a 40-micron embolic filter, which together aim to protect the brain during a transcarotid artery revascularization procedure, or TCAR, by temporarily redirecting the flow of blood away from the head and catching floating debris.